Futures
Access hundreds of perpetual contracts
TradFi
Gold
One platform for global traditional assets
Options
Hot
Trade European-style vanilla options
Unified Account
Maximize your capital efficiency
Demo Trading
Introduction to Futures Trading
Learn the basics of futures trading
Futures Events
Join events to earn rewards
Demo Trading
Use virtual funds to practice risk-free trading
Launch
CandyDrop
Collect candies to earn airdrops
Launchpool
Quick staking, earn potential new tokens
HODLer Airdrop
Hold GT and get massive airdrops for free
Launchpad
Be early to the next big token project
Alpha Points
Trade on-chain assets and earn airdrops
Futures Points
Earn futures points and claim airdrop rewards
More
Silexion Therapeutics 10-K: $11.9M net loss, cash $6.08M; operating loss $11.63M
Silexion Therapeutics reported a net loss of $11.912 million for the year ended December 31, 2025, an improvement from its $16.519 million loss in 2024. The company’s operating loss matched its operating expenses of $11.632 million, and it held $6.075 million in cash, which management deems insufficient for 12 months without additional financing. Silexion is progressing its KRAS-silencing siRNA SIL204 program and anticipates initiating clinical studies in Q2 2026 after regulatory clearance.